Avalo Therapeutics
AVTX----
Avalo Therapeutics (AVTX)
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Avalo Therapeutics Analyst Rating
View MoreForecast & Rating
Jul 23, 2026Price forecast
$44.69142.37%
Forecast & RatingStrong buy
15analysts
- Strong buy86.67%
- Buy13.33%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Simplywall · Jul 7 at 02:54 PM
What Avalo Therapeutics (AVTX)'s Russell Index Additions and Board Refresh Mean for Shareholders
- PUBT · Jul 2 at 03:07 PM
Avalo Therapeutics CMO Mittie Doyle disposes of 4,654 common shares valued at $93,080
- Unusual Whales · Jun 26 at 06:01 AM
Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes
- PUBT · Jun 25 at 04:26 PM
Avalo Therapeutics CMO Mittie Doyle disposes of 1,450 common shares valued at $26,100
- PUBT · Jun 25 at 04:24 PM
Avalo Therapeutics director Philip Ron M files initial beneficial ownership statement
- PUBT · Jun 23 at 06:00 AM
Avalo Therapeutics appoints Ron Philip to board of directors
